D
Sarepta Therapeutics, Inc. SRPT
$20.47 $0.753.80% NASDAQ
Recommendation
Prev Close
$20.47
Volume
103,327
Avg Vol (90D)
8,213,464
Market Cap
$2.14B
Dividend & Yield
--
52-Week Range
$10.42 - $131.31
P/E (TTM)
--
EPS (TTM)
-$2.90
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside
8/12/2025 - MarketBeat
Sarepta Therapeutics (SRPT, $19.72) price exceeded its 50-day Moving Average on December 01, 2025
12/2/2025 - Tickeron - Stocks
Did FDA Green Light for ELEVIDYS and Pipeline Progress Just Shift Sarepta Therapeutics' (SRPT) Narrative?
12/2/2025 - Simply Wall St
Sarepta Therapeutics (SRPT): Evaluating Valuation After FDA Progress and Pipeline Milestones
11/29/2025 - Simply Wall St
Envestnet Asset Management Inc. Decreases Stake in Sarepta Therapeutics, Inc. $SRPT
11/28/2025 - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 8.3% - Still a Buy?
11/27/2025 - MarketBeat
Is Sarepta Therapeutics a Bargain After FDA Approval and Last Week's 27.8% Rally?
11/27/2025 - Simply Wall St
Sarepta Therapeutics (SRPT, $20.95) price moved above its 50-day Moving Average on November 26, 2025
11/27/2025 - Tickeron - Stocks
Sarepta Therapeutics (SRPT, $19.35) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 25, 2025
11/26/2025 - Tickeron - Stocks
Sarepta Therapeutics, Inc. $SRPT Shares Sold by Brandywine Global Investment Management LLC
11/26/2025 - MarketBeat
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
11/25/2025 - Zacks Investment Research
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
11/25/2025 - Business Wire
ELEVIDYS Label Changes and Pipeline Progress Could Be a Game Changer for Sarepta Therapeutics (SRPT)
11/24/2025 - Simply Wall St
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
11/24/2025 - GuruFocus
Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics
11/24/2025 - Seeking Alpha - Healthcare
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
11/24/2025 - Business Wire
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
11/24/2025 - Business Wire
Sarepta Therapeutics (SRPT): Valuation Update Following ELEVIDYS Label Changes and Heightened Safety Warnings
11/22/2025 - Simply Wall St
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Recommendation of "Hold" from Analysts
11/22/2025 - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 5.3% - What's Next?
11/20/2025 - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
11/20/2025 - PR Newswire
Raiffeisen Bank International AG Has $723,000 Stock Position in Sarepta Therapeutics, Inc. $SRPT
11/20/2025 - MarketBeat
Bank of New York Mellon Corp Sells 641,805 Shares of Sarepta Therapeutics, Inc. $SRPT
11/20/2025 - MarketBeat
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
11/17/2025 - Zacks Investment Research
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
6/18/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$2.41B
EBITDA (TTM)
-$36.28M
EBIT (TTM)
-$86.01M
Net Income (TTM)
-$271.51M
Balance Sheet
Total Assets (Q)
$3.49B
Total Debt (Q)
$1.26B
Total Liabilities (Q)
$2.17B
Book Value Per Share (Q)
$12.60
Cash Flow
Cash from Operations (TTM)
-$244.64M
Cash from Investing (TTM)
$737.55M
Cash from Financing (TTM)
-$80.15M
Net Change in Cash (TTM)
$412.77M
Filings
Filing Date
Thursday, November 6, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
0.78
7-Day Total Return
15.72%
30-Day Total Return
-12.33%
60-Day Total Return
16.04%
90-Day Total Return
47.69%
Year to Date Total Return
-83.50%
1-Year Total Return
-83.76%
2-Year Total Return
-76.23%
3-Year Total Return
-83.35%
5-Year Total Return
-86.65%
52-week Low
Jul 24, 2025 - $10.42
52-week High
Dec 09, 2024 - $131.31
Valuation
Market Cap
$2.14B - Mid Cap
Enterprise Value
$2.55B
Price/Sales (TTM)
0.85
Price/Book (Q)
1.62
Dividends and Shares
Shares Outstanding
100.24
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.sarepta.com
Phone Number
617 274 4000
Address
215 First Street
Cambridge, MA 02142
Country
United States
Year Founded
1980
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic... more
NASDAQ 12/02/2025 4:00PM Eastern Quotes delayed